test

Maysa Abu-Khalaf MBBS, MD

Associate Professor of Medicine (Medical Oncology) and of Obstetrics, Gynecology, and Reproductive Sciences

Departments & Organizations

Cancer Center, Yale: Breast Cancer Program | Developmental Therapeutics

Medical Oncology

Obstetrics, Gynecology & Reproductive Sciences


Research Interests

Clinical trials evaluating novel agents for the treatment of breast; Ovarian and endometrial cancers; PI3K-mTOR inhibitors; HER-2 targeted therapies; Angiogenesis  more...


Education

  • M.B.B.S., Jordan University, 1995

Selected Publications

  • Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009 Jul 20;27(21):3430-6. Epub 2009 May 26.
  • Christy CJ, Thorsteinsson D, Grube BJ, Black D, Abu-Khalaf M, Chung GG, DiGiovanna MP, Miller K, Higgins SA, Weidhaas J, Harris L, Tavassoli FA, Lannin DR. Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol. 2009 Mar;16(3):697-702. Epub 2009 Jan 9.

more...

collapsible-single-column-one-thumbnailphotobooksupi=11629110/WCF/News.svc/

Latest News

3
more...

Edit Profile